- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02314312
Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI Donors
10. december 2014 opdateret af: CHALERMPON NA PETVICHARN, Mahidol University
A 12 Month, Single-center, Open-label, Randomized-controlled Trial to Investigate Efficacy, Safety and Tolerability of Everolimus in Combination With Cyclosporine A and Corticosteroid in de Novo Transplant Recipients of Expanded Criteria Donor Kidneys or Acute Kidney Injury
Single center, open-label randomized-control trial Population: de novo 48 kidney transplant recipients (age 18-75 years) from ECD/AKI donors Compare: everolimus with low dose CNI and prednisolone versus standard immunosuppressive regimen Objective: To evaluate efficacy of everolimus with low dose CNI in de novo kidney transplant recipients of ECD/AKI donors Primary endpoint: Mean eGFR (CKD-EPI) at 12 months post-transplantation
Studieoversigt
Status
Ukendt
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Secondary Endpoints:
- To assess renal function by means of eGFR (Cockcrault and Gault formula), at -Month 6 and 12 post-transplantation
- To assess incidence of the individual composite endpoints including BPAR, graft loss and death at Month 6 and 12 post-transplantation
- To assess the incidence and duration of renal replacement therapy
- To assess the incidence of chronic allograft nephropathy (IF/TA) at Month 12
- To assess renal function by means of serum creatinine at Month 6 and 12 post-transplantation
- To compare the overall safety and tolerability (incidence of AEs and SAEs, infections, discontinuations due to AEs, lab abnormalities, wound and surgical complications) at Month 6 and 12 post-transplantation
Definition of ECD
- Brain-dead donor > 60 years old or
- Donor age > 50 years old with two of the following criteria;
- History of HT
- Terminal SCr. ≥ 1.5 mg/dL
- Death from cerebrovascular accident Definition of AKI donor
- Brain-dead donor with an increase of SCr. ≥ 0.3 mg/dL from baseline
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
48
Fase
- Fase 3
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 75 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Age 18-75 years
- Recipients of first DDKT from ECD or AKI donors
- Patient willing to participate in the study
Exclusion Criteria:
Multi-organ recipients
- Organ donation after Cardiac Death (DCD).
- PRA > 20 % or with historical peak PRA > 50%
- Patients who lost first graft due to immunological reason within the first year post-transplantation.
- ABO incompatible transplants or positive cross-match
- Patients with chronic inflammatory bowel disease.
- Severe allergy requiring acute treatment, or any known hypersensitivity to everolimus, thymoglobulin
- Thrombocytopenia (platelet < 75,000/mm3), ANC < 1,500 /mm3 or leucopenia (leucocytes < 2,500/mm3), or Hb < 6 g/dL
- Chronic active HCV, HIV, or HBsAg positive
- History of malignancy during the last five years, except squamous or basal cell carcinoma of the skin.
- Ongoing infection requiring treatment with a systemic antibiotic.
- Patient with severe hypercholesterolemia (> 300 mg/dL) or hypertriglyceridemia (> 600 mg/dL) that cannot be controlled
- Evidence of severe liver disease.
- Severe restrictive or obstructive pulmonary disorders.
- Pregnant or nursing (lactating) women.
- Patient who refuse to participate into the study or would like to withdraw from the study.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: A: investigation arm
De novo kidney transplantation form ECD/AKI donor with Everolimus + low dose cyclosporinA + prednisolone as immunosuppressive regimen
|
|
Andet: B: control arm
De novo kidney transplantation form ECD/AKI donor with standard immunosuppressive regimen
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
eGFR (CKD-EPI)
Tidsramme: 12 months post kidney transplantation
|
12 months post kidney transplantation
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Surasak Kantachuvesiri, M.D., PH.D, Ramathibodi Hospital, Mahidol University
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. januar 2012
Primær færdiggørelse (Forventet)
1. juni 2015
Studieafslutning (Forventet)
1. juni 2015
Datoer for studieregistrering
Først indsendt
8. december 2014
Først indsendt, der opfyldte QC-kriterier
10. december 2014
Først opslået (Skøn)
11. december 2014
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
11. december 2014
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
10. december 2014
Sidst verificeret
1. december 2014
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Enzymhæmmere
- Anti-inflammatoriske midler
- Antirheumatiske midler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Dermatologiske midler
- Antifungale midler
- Calcineurin-hæmmere
- Prednisolon
- Everolimus
- Cyclosporin
- Cyclosporiner
Andre undersøgelses-id-numre
- CRAD001ATH01T
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Transplantation af nyre
-
Novosibirsk Scientific Research Institute for Circulatory...Rekrutteringat evaluere Association of GUCY1A3 rs7692387 Gene Polymorphism Carrier på udviklingen af kardiovaskulære hændelser efter koronararterie-bypass-transplantationDen Russiske Føderation
-
Prisma Health-UpstateNational Institute on Drug Abuse (NIDA); Clemson UniversityRekrutteringStandard for pleje | Standard of Care + CBT4CBT | Standard of Care + CBT4CBT + RCForenede Stater
-
Sorbonne UniversityAalborg UniversityRekrutteringPoint of Care UltralydFrankrig
-
Istanbul UniversityAktiv, ikke rekrutterende
-
Imperial College LondonAfsluttetProof Of Concept undersøgelseDet Forenede Kongerige
-
Asociacion Española Primera en SaludIntensive Care Unit Pasteur HospitalAfsluttetPoint of Care UltralydUruguay
-
NorthShore University HealthSystemUkendt
-
Aga Khan UniversityThe Hospital for Sick Children; Grand Challenges CanadaUkendtPoint of Care UltralydPakistan
-
Research Unit Of General Practice, CopenhagenUniversity of Copenhagen; Region Capital Denmark; The Copenhagen General... og andre samarbejdspartnereAfsluttet
-
Nimble Science Ltd.University of Calgary; Lallemand Health SolutionsAfsluttet
Kliniske forsøg med Everolimus + low dose cyclosporin A + prednisolone
-
University Hospital Schleswig-HolsteinUniversity of KielAfsluttetFunktion af nyretransplantationTyskland
-
London School of Hygiene and Tropical MedicineArmauer Hansen Research Institute, Ethiopia; Alert Hospital, Ethiopia; Homes...Afsluttet
-
Novartis PharmaceuticalsAfsluttetNyrefunktionDanmark, Norge, Sverige
-
London School of Hygiene and Tropical MedicineArmauer Hansen Research Institute, Ethiopia; Alert Hospital, Ethiopia; Homes...AfsluttetSpedalskhedEtiopien
-
Hannover Medical SchoolHoffmann-La RocheAfsluttetHjertetransplantationTyskland
-
Assistance Publique - Hôpitaux de ParisAfsluttet
-
London School of Hygiene and Tropical MedicineArmauer Hansen Research Institute, Ethiopia; Alert Hospital, Ethiopia; Homes...Afsluttet
-
Novartis PharmaceuticalsAfsluttet
-
NovartisAfsluttetNyretransplantation | Afvisning af transplantatForenede Stater
-
Novartis PharmaceuticalsAfsluttet